Comparative Pharmacology
Head-to-head clinical analysis: CADUET versus CARDENE IN 4 8 DEXTROSE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CADUET versus CARDENE IN 4 8 DEXTROSE IN PLASTIC CONTAINER.
CADUET vs CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amlodipine: Dihydropyridine calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes, causing vasodilation and reduced peripheral vascular resistance. Atorvastatin: HMG-CoA reductase inhibitor that competitively inhibits the conversion of HMG-CoA to mevalonate, reducing cholesterol synthesis in the liver.
Calcium channel blocker (dihydropyridine type) that inhibits the influx of calcium ions into vascular smooth muscle and cardiac muscle, leading to vasodilation and decreased myocardial contractility.
CADUET (amlodipine/atorvastatin) is available as tablets of 2.5/10, 2.5/20, 2.5/40, 5/10, 5/20, 5/40, 5/80, 10/10, 10/20, 10/40, and 10/80 mg amlodipine/atorvastatin. Initial dose depends on current antihypertensive and lipid-lowering therapy. Usual starting dose is 5/10 mg orally once daily; titrate at intervals of 2-4 weeks based on blood pressure and LDL-C goals. Maximum daily dose: amlodipine 10 mg; atorvastatin 80 mg.
Intravenous: 5 mg/hr initially, titrate by 2.5 mg/hr every 15 minutes based on response; usual maintenance 3-10 mg/hr.
None Documented
None Documented
Amlodipine: terminal half-life 30-50 h (enables once-daily dosing). Atorvastatin: terminal half-life ~14 h, but active metabolites (ortho- and para-hydroxy atorvastatin) have half-life 20-30 h; clinically, pharmacodynamic half-life (HMG-CoA reductase inhibition) is ~20-30 h.
2-4 hours (terminal); prolonged in hepatic impairment; clinical context: requires continuous IV infusion for sustained effect
Amlodipine: 60% renal (metabolites), 20-25% biliary/fecal. Atorvastatin: 1% renal (unchanged), 90% biliary/fecal (≥70% as metabolites).
Renal: 55-60% as metabolites, <1% unchanged; biliary/fecal: 35-40%
Category C
Category C
Calcium Channel Blocker + HMG-CoA Reductase Inhibitor
Calcium Channel Blocker